Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors

Background Immune checkpoint inhibitors (ICI) have become an important treatment option for non-small cell lung cancer (NSCLC). We aimed to evaluate the clinical impact of pseudoprogression (PsP) and treatment beyond RECIST1.1-defined progressive disease (TBP) on outcome in NSCLC patients treated wi...

Full description

Bibliographic Details
Main Authors: Sang Eun Won, Hyo Jung Park, Sangil Byun, Junhee Pyo, Jwa Hoon Kim, Chang-Min Choi, Jae Cheol Lee, Dae Ho Lee, Sang-We Kim, Shinkyo Yoon, Kyung Won Kim
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
carcinoma
non-small cell lung
immunotherapy
checkpoint inhibitor
response evaluation criteria in solid tumors
pseudoprogression
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1776058

Internet

http://dx.doi.org/10.1080/2162402X.2020.1776058

Similar Items